Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $40.79 -2.58%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel launches breast cancer drug Veppanu at $29,400 per month
- zSpace, Inc. (ZSPC) Reports Q2 results
- Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
